A Phase 1b Study of Abemaciclib in Combination With Pembrolizumab for Patients With Stage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 30 Nov 2017
At a glance
- Drugs Abemaciclib (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Eli Lilly
- 30 Nov 2017 According to a Merck AG media release, results from this trial will be presented at the 2017 San Antonio Breast Cancer Symposium (SABCS).
- 21 Apr 2017 Planned End Date changed from 17 Sep 2018 to 1 Dec 2018.
- 21 Apr 2017 Planned primary completion date changed from 15 Mar 2018 to 1 May 2018.